Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/46946

TitleIn vitro and ex-vivo permeability studies of paclitaxel and doxorubicin from drug-eluting biodegradable ureteral stents
Author(s)Barros, Alexandre António Antunes
Oliveira, Carlos
Reis, R. L.
Lima, Estêvão Augusto Rodrigues de
Duarte, Ana Rita C.
KeywordsBiodegradable polymers
Doxorubicin permeability
Paclitaxel
Upper tract urothelial carcinoma
Ureteral stents
Issue dateFeb-2017
PublisherElsevier Inc.
JournalJournal of Pharmaceutical Sciences
CitationBarros A. A., Oliveira C., Reis R. L., Lima E., Duarte A. R. C. In vitro and ex-vivo permeability studies of paclitaxel and doxorubicin from drug-eluting biodegradable ureteral stents, Journal Of Pharmaceutical Sciences, doi:10.1016/j.xphs.2017.02.023, 2017
Abstract(s)A drug-eluting biodegradable ureteral stent (BUS) has been developed as a new approach for the treatment of urothelial tumors of upper urinary tract cancer. In a previous work, this system has proven to be a good carrier for anticancer drugs as a potential effective and sustainable intravesical drug delivery system. BUS has revealed to reduce in 75% the viability of human urothelial cancer cells (T24) after 72 h of contact and demonstrated minimal cytotoxic effect on human umbilical vein endothelial cells (HUVECs) which were used as a control. In this work, we studied the permeability of the anticancer drugs, such as paclitaxel and doxorubicin, alone or released from the BUS developed. We used 3 different membranes to study the permeability: polyethersulfone (PES) membrane, HUVECs cell monolayer, and an ex vivo porcine ureter. The ureter thickness was measured (864.51 mm) and histological analysis was performed to confirm the integrity of urothelium. Permeability profiles were measured during 8 h for paclitaxel and doxorubicin. The drugs per se have shown to have a different profile and as expected, increasing the complexity of the membrane to be permeated, the permeability decreased, with the PES being more permeable and the ex vivo ureter tissue being less permeable. The molecular weight has also shown to influence the permeability of each drug and a higher percentage for doxorubicin (26%) and lower for paclitaxel (18%) was observed across the ex vivo ureter. The permeability (P), diffusion (D), and partition (Kd) coefficients of paclitaxel and doxorubicin through the permeable membranes were calculated. Finally, we showed that paclitaxel and doxorubicin drugs released from the BUS were able to remain in the ex vivo ureter and only a small amount of the drugs can across the different permeable membranes with a permeability of 3% for paclitaxel and 11% for doxorubicin. The estimated amount of paclitaxel that remains in the ex vivo ureter tissue is shown to be effective to affect the cancer cell and not affect the noncancer cells.
TypeArticle
URIhttp://hdl.handle.net/1822/46946
DOI10.1016/j.xphs.2017.02.023
ISSN0022-3549
e-ISSN1520-6017
Publisher versionhttp://www.jpharmsci.org/article/S0022-3549(17)30132-6/pdf
Peer-Reviewedyes
AccessRestricted access (UMinho)
Appears in Collections:3B’s - Artigos em revistas/Papers in scientific journals

Files in This Item:
File Description SizeFormat 
19009-Alex-Barros-Paper.pdf
  Restricted access
2,08 MBAdobe PDFView/Open    Request a copy!

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID